259543-76-5

Upstream product

• 1402586-33-7 2-(3-fluoro-4-(methylthio)phenyl)-2-oxoacetic acid 
• 1402586-32-6 ethyl 2-(3-fluoro-4-(methylthio)phenyl)-2-oxoacetate 
• 655-20-9 2-fluorothioanisole 
• 2557-78-0 2-fluorothiophenol 

Downstream Products

• 1402586-35-9 methyl 2-(3-fluoro-4-(methylthio)phenyl)propanoate 
• 1402586-36-0 methyl 2-(3-fluoro-4-(methylsulfonyl)phenyl)propanoate 
• 1402586-37-1 2-(3-fluoro-4-(methylsulfonyl)phenyl)propanoic acid 
• 1255040-87-9 N-[[5-tert-butyl-2-(3-chlorophenyl)-2H-pyrazol-3-yl]methyl]-2-(3-fluoro-4-methylsulfonylphenyl)propionamide 
• 1402581-95-6 N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methyl]-2-(3-fluoro-4-methylsulfonyl-phenyl)propionamide 
• 1402586-34-8 2-(3-fluoro-4-(methylthio)phenyl)propanoic acid 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN SO2-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a S02-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.